ARVN Arvinas Inc

Price (delayed)

$43.35

Market cap

$2.3B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$4.18

Enterprise value

$2.24B

Arvinas is a clinical-stage biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing ...

Highlights
The gross profit has grown by 40% from the previous quarter
Arvinas's revenue has increased by 40% from the previous quarter
The quick ratio has dropped by 63% year-on-year but it is up by 3.2% since the previous quarter
The company's equity rose by 18% YoY but it fell by 7% QoQ
The company's net income has shrunk by 54% YoY and by 12% QoQ
The debt rose by 36% since the previous quarter

Key stats

What are the main financial stats of ARVN
Market
Shares outstanding
53.17M
Market cap
$2.3B
Enterprise value
$2.24B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
3.18
Price to sales (P/S)
35.15
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
34.34
Earnings
Revenue
$65.36M
EBIT
-$208.85M
EBITDA
-$202.21M
Free cash flow
$535.46M
Per share
EPS
-$4.18
Free cash flow per share
$10.1
Book value per share
$13.64
Revenue per share
$1.23
TBVPS
$28.08
Balance sheet
Total assets
$1.49B
Total liabilities
$765M
Debt
$6.8M
Equity
$723.3M
Working capital
$1.22B
Liquidity
Debt to equity
0.01
Current ratio
6.12
Quick ratio
6.05
Net debt/EBITDA
0.3
Margins
EBITDA margin
-309.4%
Gross margin
100%
Net margin
-326.6%
Operating margin
-326.9%
Efficiency
Return on assets
-16.1%
Return on equity
-29.4%
Return on invested capital
-20.3%
Return on capital employed
-16.7%
Return on sales
-319.5%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ARVN stock price

How has the Arvinas stock price performed over time
Intraday
1.57%
1 week
9.77%
1 month
0.37%
1 year
-43.12%
YTD
-47.22%
QTD
-35.59%

Financial performance

How have Arvinas's revenue and profit performed over time
Revenue
$65.36M
Gross profit
$65.36M
Operating income
-$213.65M
Net income
-$213.44M
Gross margin
100%
Net margin
-326.6%
The company's net income has shrunk by 54% YoY and by 12% QoQ
Arvinas's operating margin has soared by 52% YoY and by 22% from the previous quarter
The net margin has surged by 50% year-on-year and by 20% since the previous quarter
ARVN's operating income is down by 49% YoY and by 9% from the previous quarter

Growth

What is Arvinas's growth rate over time

Valuation

What is Arvinas stock price valuation
P/E
N/A
P/B
3.18
P/S
35.15
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
34.34
The EPS has contracted by 27% YoY and by 9% from the previous quarter
The stock's price to book (P/B) is 43% less than its last 4 quarters average of 5.5
The company's equity rose by 18% YoY but it fell by 7% QoQ
The P/S is 73% below the last 4 quarters average of 126.1
Arvinas's revenue has increased by 40% from the previous quarter

Efficiency

How efficient is Arvinas business performance
The company's return on invested capital has surged by 73% YoY and by 14% QoQ
The ROS has soared by 51% YoY and by 22% from the previous quarter
ARVN's return on assets is up by 44% year-on-year and by 4.7% since the previous quarter
ARVN's return on equity is up by 12% year-on-year but it is down by 8% since the previous quarter

Dividends

What is ARVN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ARVN.

Financial health

How did Arvinas financials performed over time
ARVN's total assets is 95% more than its total liabilities
ARVN's total assets has soared by 118% YoY but it is down by 6% from the previous quarter
ARVN's current ratio has shrunk by 63% YoY but it is up by 3.2% QoQ
The debt is 99% smaller than the equity
The debt rose by 36% since the previous quarter
The company's equity rose by 18% YoY but it fell by 7% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.